Status:
COMPLETED
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
Lead Sponsor:
AmpliMed Corporation
Conditions:
Non-small Cell Lung Cancer
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer. Docetaxel is app...
Eligibility Criteria
Inclusion
- Be diagnosed with previously treated breast, lung, or prostate cancer where docetaxel is indicated.
- Prior treatment; at least one prior regimen required.
- Able to perform the activities of daily living.
- Off prior cancer therapy for at least 4 weeks.
- If female neither pregnant nor nursing.
- Willing to use contraceptives to prevent pregnancy.
- No other serious illnesses.
- No other active malignancy.
- No serious infections.
- No other current drug therapy for the cancer.
- Blood counts and blood chemistries in or near normal range.
- Prior radiation is permitted.
Exclusion
- Active brain metastases.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00327288
Start Date
October 1 2005
End Date
July 1 2008
Last Update
June 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site 008
Houston, Texas, United States, 77030